close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oruka Therapeutics, Inc. - Common Stock (NQ:ORKA)

89.92 -4.62 (-4.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Oruka Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces New Board Member and Board Transition
Appoints accomplished commercial leader Chris Martin to its Board of Directors 
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Present at Multiple November Investor Conferences
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces $180 Million Private Placement
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Present at Multiple March Investor Conferences
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
From Oruka Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.